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of an anti-hypertensive medication combination and compared with current care 
(23.9% BP control rate). 100,000 hypertensive simulated individuals were modeled 
over a 10 year time horizon. Outcomes of major adverse cardiovascular events; stroke, 
myocardial infarction (MI) and CV death were reported. Direct health care costs of 
strokes and MIs were derived from official Russian statistics and price lists. Results: 
To achieve SBP control rates of 30%, 40%, 50%, and 60%, adherence rates to the anti- 
hypertensive treatment program were 11.1%, 29.4%, 47.6%, and 65.9% respectively. CV 
death relative risk reductions were 5.0%, 13.2%, 21.4%, and 29.6%, respectively. For the 
current estimated 43,855,000 person Russian hypertensive population, each control 
rate scenario resulted in an absolute reduction of 398,097, 1,050,715, 1,703,334 and 
2,355,952 CV deaths, and a reduction of 458,781, 1,210,881, 1,962,981, and 2,715,081 
stroke/MI diagnoses. Averted direct costs from current care (225,781) were 12,834, 
33,873, 54,913 and 75,952 million Rubles, respectively. ConClusions: Our simulation 
implies that a clinically significant number of CV events in the Russian hypertensive 
population may be prevented by achieving BP control through an antihypertensive 
drug combination. Averted costs may be re-allocated to strengthen evidence-based, 
preventive interventions.
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objeCtives: To describe UK patients with acute coronary syndrome (ACS) who 
receive percutaneous coronary intervention (PCI) or are medically managed only 
(MM) and evaluate factors affecting approaches to treatment. Methods: Patients 
registered with a general practice participating in the Clinical Practice Research 
Datalink (CPRD) with Hospital Episode Statistics (HES)-linked data were included 
if they had an ACS-related hospitalization (January 2008-December 2009). Logistic 
regression analyses were used to assess what characteristics at ACS-related hospi-
talization date were associated with PCI or MM classified at 30-days post-hospital-
isation date (30DHD). Results: A total of 10,753 ACS patients were identified (60% 
male, 67% aged ≥ 65, 81% had NSTEMI or UA at index date); 30DHD, 74% were MM 
and 26% had PCI. Factors associated with receiving PCI were STEMI at hospitalization 
(OR 3.73, 95% CI 3.30, 4.22); patients with previous PCI pre-hospitalization (OR 1.29, CI 
1.07, 1.55) and current smokers (OR 1.16, CI 1.02, 1.32). Patients less likely to receive 
PCI included women (OR 0.67, CI 0.60, 0.75), those with previous ACS hospitaliza-
tion (OR 0.69, CI 0.59, 0.80), those prescribed: statins 12 months pre-hospitalization 
date (OR 0.75, CI 0.67, 0.85), diuretics (OR 0.72, CI 0.61, 0.85), ACE inhibitors (OR 
0.84, CI 0.75, 0.95), proton pump inhibitors (OR 0.86, CI 0.77, 0.96), those previously 
diagnosed with congestive heart disease (OR 0.54, CI 0.42, 0.71), atrial fibrillation 
(OR 0.67, CI 0.54, 0.83), stroke/TIA (OR 0.77, CI 0.63, 0.93) or renal disease (OR 0.82, 
CI 0.71, 0.95). Age and BMI were significant as continuous variables with non-linear 
effects. ConClusions: This is the first large-scale UK study using real-world data 
to assess socio-demographic and clinical predictors for PCI in ACS, and indicates 
that NSTE-ACS patients and those with comorbidities are more likely to be MM. This 
will be discussed in light of current treatment of STEMI and NSTE-ACS in the EU.
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objeCtives: To analyze the current state and the trends of pharmacoeconomic 
research in cardiology in Russia. Methods: We have reviewed all main databases 
of scientific publications (PubMed, eLibrary.ru etc.) as well as individual journals, 
conference abstracts and web-sites for the period 2007–2013. Results: It was found 
that cardiology becomes one of the most popular topics for pharmacoeconomists, 
partly because of its significance for public health and the growing amount of state 
funding for the prevention of CVD in recent years. Cardiovascular problems make up 
16-25% of congress abstracts and 26% of applications for Da.Signa, the only award in 
pharmacoeconomics in Russia. Most publications in our analysis dealt with arterial 
hypertension (44%), coronary heart disease (16%) and chronic heart failure (7%). A 
wide range of original and generic drugs were included into these researches, how-
ever in most cases there was a prevalence of cost-efficiency analysis and modeling 
methods based on the results of non-Russian clinical trials and meta-analyses. 
Overwhelming majority of the results were published in Russian and therefore are 
not available for the non-Russian-speaking reader. ConClusions: During the last 
five years, a great number of pharmacoeconomic research in cardiology have been 
performed and published. However, there is a need of clinical trials that would con-
sider the Russian specifics and health care standards. Pharmacoeconomic analysis 
should become an integral part of clinical trials, especially in case of drug therapy 
of myocardial infarction, stroke and other conditions, where the differences exist 
between the Russian and foreign practice. Some of the analyzed publications should 
be updated because of the recent changes in health care standards.
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objeCtives: To analyze the volume-outcome relationship for patients with intact 
abdominal aortic aneurysm (AAA) and hip fracture (HIP) and define hypothetical 
minimum volume standards to assess changes in access. Methods: The analy-
sis is based on administrative data coming from the German system of diagnosis 
related groups of about 18.6 million hospital cases of 1780 German hospitals for the 
year 2007. The data includes detailed information on patient characteristics used for 
Re-hospitalisations were taken into account if they occurred after one month fol-
lowing inclusion and regardless of the location of the hospital at the national level. 
Alternatively, ‘all’ re-hospitalisations rates regardless the related diagnosis were also 
assessed. Inpatient costs were valued based on reference tariffs according to French 
National Social Health Payer perspective. Results: Around 1750 patients were fol-
lowed per cohort across the four hospitals starting from 2009, 2010 and 2011. One-
year re-hospitalisations rates for ST and TI ranged from 2.9% to 7.1%. The median 
time to re-hospitalisation ranged between 1.5 to 9.3 months. Two-year re-hospitali-
sations rates for ST and TI ranged from 4.5% to 10.4%. Two-year re-hospitalisations 
rates regardless of related diagnosis in acute and/or rehabilitative settings ranged 
between 45.5% to 65.1%. Mean costs (+/-SD) per inpatient stay for ST and TI were 
4’645€ (+/-3’821) in acute setting (2013 EUR). When excluding TI, mean costs were 
5’293€ +/-4’225€ . Hospitalization costs varied depending on sub-type of stroke, sever-
ity, co-morbidities and also year of costing. ConClusions: Such short term data 
on recurrence rates and inpatient costs might be useful when estimating potential 
benefits of any secondary prevention intervention aiming at reducing stroke relapses.
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objeCtives: We examined the economic consequences of generic switching within 
the statin market for public plans in Canada between 2000 and 2012. Methods: 
We extracted data (number of units, costs, and claims) for all statins reimbursed 
by Canadian public drug plans for the period 2000-2012 (sources: IMS Brogan and 
Canadian Institute for Health Information). Results: Public plans paid $11.2 BN to 
reimburse statins for 2 MM patients between 2000 and 2012. The annual cost of reim-
bursing statins peaked at $1.3 BN in 2009. Generic atorvastatin was listed by public 
plans in 2010, and the proportion of statin reimbursement attributable to generics 
increased from 18% in 2009 to 75% in 2012, reflecting a 76% increase in generic switch-
ing. During the same period, the unit cost of brands and generics fell by 25% and 49%, 
respectively. The combined effect of increased generic switching and lower unit costs 
resulted in a 55% decrease in the total cost of statins, from $1.3 BN in 2009 to $582 MM 
in 2012. Annual savings attributable to generic switching increased 10-fold between 
2000 and 2012, from $7 to $709 MM. The efficiency at which potential savings has been 
captured through generic switching increased from 8% to 74% from 2000 to 2012; we 
project that this will generate savings of ~$800 MM annually through 2015. Increasing 
generic switching to 100% could generate up to an average of $135 MM annually in 
additional savings ConClusions: Although substantial savings have been gener-
ated by generic switching within the statin class, increasing generic switching could 
generate additional savings. One strategy to capture these additional savings would 
be disinvestment: if branded statins were de-listed from public plans if a generic ver-
sion were available, this would increase generic switching, increase the efficiency at 
which potential savings are captured, and increase total savings.
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objeCtives: To estimate the Disability Adjusted Life-Years (DALY) attributable to 
Atrial Fibrillation (AF) during 2010 in Portugal, including both AF and AF related 
stroke. Methods: The analysis requires two types of data. The first is an extended 
set of epidemiological data, which resulted from a compilation of the prevalence and 
mortality data for AF and for stroke in Portugal. For the distribution of mortality by 
age, gender and cause of death the WHO Europe mortality database was used. The 
analysis also uses the results of FAMA, a study of the prevalence of AF in Portugal. 
Incidence rates were estimated from a review of the international literature. The 
second type of data concerns the relative risk (RR) of stroke for patients with AF. 
RR values by age group from the Framingham Study were used. Disability weights 
were taken from the Global Burden of Disease 2010. Results: A total of 3863 deaths 
in Portugal in 2010 were related to AF, with 813 having AF listed as cause of death 
and the remaining 3.050 being stroke deaths attributable to AF. The AF attributable 
deaths are roughly 3.6% of total deaths in the country. The estimate total DALYs 
was 9.814 (2.251 for AF listed as the cause of death and 7.563 for stroke as cause of 
death attributed to AF). ConClusions: AF is an important cause of disease burden 
in Portugal. As reference, AF DALYs are roughly twice the estimated DALYs for skin 
cancer. AF should receive adequate attention from policy makers.
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objeCtives: Russia faces a high burden of cardiovascular (CV) disease. Prevalence 
of all CV risk factors, especially hypertension, is high. Elevated blood pressure (BP) 
is generally poorly controlled, and medication usage is suboptimal. With a disease 
model simulation we assessed the impact of improved systolic blood pressure (SBP) 
control on the number and costs of CV events potentially averted in the hypertensive 
Russian population. Methods: The Archimedes Model, a detailed computer model 
of human physiology, disease progression, and health care delivery was adapted to 
the Russian setting. Intervention scenarios of achieving SBP control rates (defined as 
SBP < 140) of 30%, 40%, 50%, and 60% were simulated by modifying adherence rates 
